First Light Diagnostics, a developer of breakthrough automated products
for rapid, sensitive, and cost-effective diagnosis of life-threatening,
antibiotic-resistant infections, today announced the acceptance of two
posters as part of the 30th Annual European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID).
With global resources focused on combating the current COVID-19
pandemic, ECCMID and similar events have been canceled or postponed. The
European Society of Clinical Microbiology and Infectious Diseases plans
to post the Abstract Book at www.escmid.org. The two posters are entitled, œAn Ultrasensitive Test for the Detection of Clostridiodes difficile
Toxins in Stool Samples Using a Single-Molecule Counting Method and
œAn Ultrasensitive Rapid Single Molecule Counting Method Detects Bacillus anthracis
Lethal Factor Directly in Blood Samples. Each highlights results and
conclusions for a novel test using First Light's MultiPath„¢ platform. œWe were excited to have been chosen to share the results of testing
on the First Light Diagnostics MultiPath platform, said Don Straus,
Founder and Chief Scientific Officer at First Light Diagnostics. œLike
all businesses, we understand the difficult decisions that had to be
made during this global crisis and look forward to sharing our posters
in-person at the appropriate time. The results presented demonstrate the speed, accuracy, and
ease-of-use of First Light's two ultrasensitive SensiTox„¢ tests for
bacterial toxins that cause life-threatening disease1. The company's SensiTox C. difficile Toxin Test will be used to diagnose patients with C. difficile
infection, the most common life-threatening hospital-acquired
infection. The data reported support the potential of the test to
deliver results within 40-minutes with minimum hands-on time and higher
accuracy than current tests. The work on the SensiTox B. anthracis
Toxin Test demonstrates a unique combination of advantages, including
ultrasensitivity, a 20-minute time to result, and no manual sample
preparation steps. Both tests use First Light's proprietary technology
for single-molecule counting and are performed on the MultiPath
Analyzer, featuring walk-away automation, high-throughput, and
random-access on-demand processing. First Light Diagnostics has
completed a clinical study for C. difficile and the submission is under review at FDA. About First Light Diagnostics, Inc. First Light Diagnostics is developing and intends to commercialize a
unique range of breakthrough diagnostic products to rapidly,
sensitively, and cost-effectively detect life-threatening infections, to
determine effective antibiotics at the onset of infection, and to
attenuate the spread of antibiotic resistance. Don Straus is the
company's Founder and primary inventor of the company's core scientific
technology. Based on its proprietary MultiPath detection technology,
First Light's products combine the clinical performance of the most
advanced commercial laboratory tests with speed, cost-effectiveness, and
ease-of-use. This will improve patient outcomes, reduce healthcare
costs, and prevent inappropriate use of powerful antibiotics. Learn more
www.firstlightdx.com Source - https://www.newswire.com/news/first-light-diagnostics-posters-and-abstracts-accepted-part-of-eccmid-21148974
| Company Name | Contact Person | Contact Number | Email Id | Website | Address |
|---|---|---|---|---|---|
| FIRST LIGHT DIAGNOSTICS | 8589979641 | dmacdonald@firstlightdx.com | https://www.firstlightdx.com/ |
Resonant Botanicals has introduced their latest flagship product, ROYAL. This brand-new formula draws on the comments of long time customers about...Read More
First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, ...Read More
science-backed prenatal products helping couples conceive healthy pregnancies, today announced the launch of its first line of clean, science-backed m...Read More
Tabula Rasa Ventures, a venture capital firm dedicated to building an impact-focused, community-led psychedelic industry, announced the launch ...Read More
The American Society of Ketamine Physicians (ASKP) was formed in 2016 after the original founders met at the KRIYA conference and chose to form...Read More
